安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究

安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究

杨斌,谢辉,王春平,孔惠芳,张伟,毛薇

解放军第302医院,解放军第302医院,解放军第302医院,解放军第302医院,解放军第302医院,解放军第302医院

收稿日期:2017-12-08 修回日期:2017-12-18 出版日期:2017-12-25
基金资助:
国家自然科学基金资助项目（项目编号：81271848；项目名称：慢性丙肝患者体内髓源性抑制细胞抑制T细胞的作用及其临床意义）

Study on Inhibition of Arotinib on Human Intrahepatic Cholangiocarcinoma Cell Line HCCC-9810

YANG Bin,XIE Hui,WANG Chunping,KONG Huifang,ZHANG Wei and MAO Wei

Beijin 302 hospital,The 302 Hospital of PLA,The 302 Hospital of PLA,The 302 Hospital of PLA,The 302 Hospital of PLA,The 302 Hospital of PLA

Received:2017-12-08 Revised:2017-12-18 Online:2017-12-25

摘要/Abstract

摘要： 目的：检测安罗替尼（Anlotinib）对人肝内胆管细胞癌(ICC)细胞系HCCC-9810的杀伤作用。方法：使用系列浓度的Anlotinib以及作为对照的索拉非尼（Sorafenib）和舒尼替尼（Sunitinib）处理HCCC-9810细胞后，进行MTT实验，利用MTT数据计算药物作用的抑制率与半数作用浓度（IC50）。在此基础上检测药物对HCCC-9810细胞转移与侵袭的影响。结果： Anlotinib、Sorafenib和Sunitinib等作用于HCCC-9810细胞的IC50值分别为（0.97±0.14）、（8.27±1.17）和（8.18±0.82）μmol·L-1。相同浓度下（1μmol·L-1），Anlotinib能显著抑制HCCC-9810细胞的转移与侵袭，Sorafenib和Sunitinib抑制作用不明显。结论：Anlotinib能够杀伤肝内胆管上皮肿瘤细胞，是肝脏胆管细胞癌诊疗新的希望。

Abstract: Objective：To identify the potential application of anlotinib on human intrahepatic cholangiocarcinoma(ICC)cell line HCCC-9810.Methods：After treatment of HCCC-9810 cells with serial concentrations of anlotinib， sorafenib and sunitinib as controls，MTT experiments were performed. Inhibition rate and IC50 were analyzed by MTT-assays.The invasion or migration of HCCC-9810 cells was identified by tranwell assays.Results：The IC50 value of anlotinib， sorafenib and sunitinib on HCCC-9810 cells was (0.97±0.14)， (8.27±1.17)， and (8.18±0.82)μmol·L-1， respectively. At the same concentration (1μmol·L-1 )， anlotinib could significantly inhibit the metastasis and invasion of HCCC-9810 cells.The inhibitory effects of sorafenib and sunitinib were not obvious.Conclusion： Anlotinib can kill intrahepatic bile duct epithelial tumor cells， and may be a hopeful strategy for intrahepatic cholangiocarcinoma treatment.

杨斌,谢辉,王春平,孔惠芳,张伟,毛薇. 安罗替尼对人肝内胆管细胞癌细胞系HCCC-9810作用研究[J]. .

YANG Bin,XIE Hui,WANG Chunping,KONG Huifang,ZHANG Wei and MAO Wei. Study on Inhibition of Arotinib on Human Intrahepatic Cholangiocarcinoma Cell Line HCCC-9810[J]. .

参考文献

2. Ali AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD. Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis. Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730. [Epub ahead of print]
Ali AH, Tabibian JH, Naser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD. Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis. Hepatology. 2017 Dec 15. doi: 10.1002/hep.29730. [Epub ahead of print]
[3] GYAWALI B，PRASAD V. Me too-drugs with limited benefits - the tale of regorafenib for HCC [J]. Nat Rev Clin Oncol，2017，Nov 28. doi: 10.1038/nrclinonc.2017.190. [Epub ahead of print]
[4] KOU P，ZHANG Y，SHAO W, et al. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review [J]. Oncotarget，2017，8(12)：20510-20515.
[5] WANG FS，FAN JG，ZHANG Z，et al. The global burden of liver disease: the major impact of China [J]. Hepatology，2014，60(6)：2099-2108.
[6] YAN Z，ZENG J，YU Y，et al. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA [J]. J Hepatol，2017，66(6)：1149-1157.
[7] CHAN AW，CHONG CC，MO FK，et al. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma [J]. J Gastroenterol Hepatol，2016，31(10)：1766-1772.
[8] JIA H，YANG Q，WANG T，et al. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents [J]. Biochim Biophys Acta，2016，1860(7)：1417-1430.
[9] XIE H，YU H，TIAN S，et al. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis [J]. Oncotarget，2017 Aug 10. doi.org/10.18632/oncotarget.20119 [Epub ahead of print]
[10] ZHAO JX，YUAN YW，CAI CF，et al. Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis [J]. Oncotarget，8(40)：66987-67000.
[11] BAI YC，HSIA YC，LIN YT，et al. Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells [J]. Anticancer Res，37(11)：6347-6353.
[12] YIP CW，LAM CY，POON TCW，et al. Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma [J]. BMC Cancer，2017，17(1)：409.
[13] XU D，JIN J，YU H，et al. Chrysin inhibited tumor glycolysis and induced apoptosis in hepatocellular carcinoma by targeting hexokinase-2 [J]. J Exp Clin Cancer Res，2017，36(1)：44.
[14] LI L，CHE L，WANG C，et al. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice [J]. Mol Imaging Biol，2016，18(3)：360-367.
[15] HSU CC，WU LC，HSIA CY，et al. Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs [J]. Oncol Rep，2015，34(3)：1620-1628.
[16] LI L，KANG L，ZHAO W，et al. miR-30a-5p suppresses breast tumor growth and metastasis through inhibition of LDHA-mediated Warburg effect [J]. Cancer Lett，2017，400：89-98.
[17] ZHAO J，HUANG X，XU Z，et al. LDHA promotes tumor metastasis by facilitating epithelial?mesenchymal transition in renal cell carcinoma [J]. Mol Med Rep，2017，16(6)：8335-8344.
[18] Luká?ová-Chomisteková Z，Culková E， Bellová R，et al. Voltammetric detection of antimony in natural water on cathodically pretreated microcrystalline boron doped diamond electrode: A possibility how to eliminate interference of arsenic without surface modification [J]. Talanta，2018，178：943-948.
[19] TAMAI T，HAYATO S，HOJO S，et al. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses [J]. J Clin Pharmacol，2017，57(9)：1138-1147.
[20] NIU L，LIU L，YANG S，et al. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies [J]. Biochim Biophys Acta，2017，1868(2)：564-570.

快速检索引用检索图表检索高级检索